Conditions: Multiple Sclerosis
Keywords: Ambulation
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 43
Healthy volunteers: no

Brief summary:
A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis

Detailed description:
This is a parallel-group, double-blind, randomized controlled crossover trial with a 1:1 randomization. There are two treatment periods of 4 weeks and a two-week off treatment washout period. Treatment periods are DER (dalfampridine ER) followed by placebo (group A) and placebo followed by DER (group B), respectively. All dosages will be administered twice a week. Purpose of the study is to see if using the study drug(dalfampridine Er) for a short period of time will improve the way subjects with multiple sclerosis (MS) walk.

Arms:
arm 1: 4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control arm 2: placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid

Interventions: intervention 1: dalfampridine ER intervention 2: placebo
Intervention descriptions: intervention 1: dalfampridine ER 10mg bid for 4 weeks intervention 2: identical placebo tablet administered bid for four weeks

Protocol document: